1. Profile of an Ideal Antianginal Agent

   • Eliot J. Lazar
   • William H. Frishman

   Section 1: The Profile of Epanolol: A New Antianginal Agent 29 November 2012 Pages: 1 - 8

2. Blood Pressure Control and Mortality — Is there a J-Shaped Curve?

   • Hans Wedeldh

   Short Communication 29 November 2012 Pages: 9 - 9

3. Pharmacokinetics of Epanolol (ICI 141,292) in Healthy Young Volunteers and Comparative Data in Elderly Patients with Angina and Subjects with Renal or Hepatic Impairment

   • I. D. Cockshott

   Section 1: The Profile of Epanolol: A New Antianginal Agent 29 November 2012 Pages: 10 - 17

4. Clinical Pharmacology of Epanolol Pharmacodynamic Aspects

   • J. D. Harry

   Section 1: The Profile of Epanolol: A New Antianginal Agent 29 November 2012 Pages: 18 - 27

5. Epanolol

   • Fawaz Akhras
   • Graham Jackson

   Section 1: The Profile of Epanolol: A New Antianginal Agent 29 November 2012 Pages: 28 - 34

6. Dose Finding in Angina — Results with Epanolol

   • T. M. Omland
   • C. v. Brandis
   • A. M. Abrahamsen

   Short Communication 29 November 2012 Pages: 35 - 38

7. Effect of Partial Agonist Activity on the Side Effects of β-Blockade in Patients with Chronic Stable Angina

   • John Chambers
   • MeiLin Ong
   • Graham Jackson

   Section 1: The Profile of Epanolol: A New Antianginal Agent 29 November 2012 Pages: 39 - 44

8. Results of a Long Term Multicentre Study in Sweden

   • J. Boberg

   Short Communication 29 November 2012 Pages: 45 - 45

9. Discussion: Section 1

   • A. Reale

   Section 1: The Profile of Epanolol: A New Antianginal Agent 29 November 2012 Pages: 46 - 48

10. Chairman’s Comments: Section 1

    • A. Reale

    Section 1: The Profile of Epanolol: A New Antianginal Agent 29 November 2012 Pages: 49 - 49

11. Rationale and Statistical Methodology for the VISA Studies

    • M. J. Ratcliffe
    • M. J. Godley

    Section 2: Epanolol in Stable Angina: The Visa Studies 29 November 2012 Pages: 50 - 54

12. Comparative Multicentre Study of the Tolerability and Efficacy of Epanolol versus Metoprolol in Patients with Stable Angina Pectoris

    • N. Clark-Turner

    Section 2: Epanolol in Stable Angina: The Visa Studies 29 November 2012 Pages: 55 - 60

13. Comparative Multicentre Study of the Tolerability and Efficacy of Epanolol versus Nifedipine in Patients with Stable Angina Pectoris

    • A. S. Readman

    Section 2: Epanolol in Stable Angina: The Visa Studies 29 November 2012 Pages: 61 - 65

14. Efficacy of Epanolol versus Metoprolol in Angina Pectoris

    • Lars Rydén
    • the Swedish Multicenter Study Group

    Short Communication 29 November 2012 Pages: 66 - 66

15. Effects of Epanolol and Metoprolol on the Heart Measured by 24-Hour Holter Monitoring

    • Adrie J. A. M. Withagen
    • H. M. A. Corbeij
    • A. Vermeulen

    Section 2: Epanolol in Stable Angina: The Visa Studies 29 November 2012 Pages: 67 - 69

16. Left Ventricular Function during Treatment with Either Metoprolol or Epanolol

    • T. Evans

    Short Communication 29 November 2012 Pages: 70 - 70

17. The Effects of Epanolol on Quality of Life

    • Sverker Jem

    Section 2: Epanolol in Stable Angina: The Visa Studies 29 November 2012 Pages: 71 - 74

18. Discussion: Section 2

    • A. J. Camm
    • L. Rydén

    Section 2: Epanolol in Stable Angina: The Visa Studies 29 November 2012 Pages: 75 - 79

19. Chairman’s Comments: Section 2

    • A. J. Camm

    Section 2: Epanolol in Stable Angina: The Visa Studies 29 November 2012 Pages: 80 - 80

20. An Overview of Clinical Trial Experience with Epanolol

    • P. Blake

    Section 3: Patient Preference: The Ultimate Determinant 29 November 2012 Pages: 81 - 85

21. Panel Discussion

    • A. J. Dunning

    Section 3: Patient Preference: The Ultimate Determinant 29 November 2012 Pages: 86 - 91